Navigation Links
Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idec's Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
Date:9/3/2013

BURLINGTON, Mass., Sept. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed neurologists consider Biogen Idec's Tecfidera to be a breakthrough in the treatment of multiple sclerosis (MS), slightly greater than those who feel the same about Novartis's Gilenya and nearly twice as many as for Genzyme's Aubagio. Conversely, less than one-third of surveyed managed care organization (MCO) pharmacy directors/medical directors (PDs/MDs) identify Gilenya, Aubagio or Tecfidera as breakthrough treatments, perhaps underscoring their decision to most commonly cover all three oral agents on nonpreferred tiers in their largest commercial plans. Notably, approximately one-quarter of surveyed MCO PDs/MDs did not cover Aubagio or Tecfidera at the time the survey was fielded, which is likely due to the recent launches of these agents. 

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The U.S. Physician and Payer Forum report entitled The Rapidly Evolving Multiple Sclerosis Treatment Landscape: How Are U.S. Physicians and Payers Responding to the Influx of New Disease-Modifying Therapies?  also finds that two emerging products, Biogen Idec's Plegridy (a pegylated version of Biogen Idec's Avonex) and Teva's Copaxone 40 mg/ml, dosed three-times weekly (a reformulation of Teva's once-daily 20mg/ml Copaxone), will experience usage patterns and market access positioning similar to those of their respective predecessor compounds. This finding suggests that physicians and payers consider the clinical value of these new products to be sufficient to drive use and coverage, but that they lack strong differentiation from their respective predecessor compounds.

The report also finds that novel late-stage emerging disease-modifying therapies (DMTs) for the treatment of MS—Genzyme/Bayer HealthCare's Lemtrada, Biogen Idec/AbbVie's daclizumab and Roche/Genentech's ocrelizumab—will generally be reserved for treatment-refractory patients, likely reflecting safety concerns about each. Furthermore, while surveyed MCO PDs/MDs anticipate formulary coverage of these DMTs on their commercial plans broadly similar to their coverage of existing DMTs, the new entrants are more likely to be subject to indications restrictions than current DMTs and emerging reformulations.

"As more DMTs enter the MS market in the U.S., uptake and coverage of each agent will depend on clear demonstration of its value to stakeholders, driven in particular by the balance of cost, advancements in efficacy and acceptable safety," said Decision Resources Senior Director Jonathan Searles. "Moreover, MCO PDs/MDs indicate that post-marketing studies supporting the health economic benefits of a DMT will be an influential factor in determining future formulary coverage—as a result, generating compelling evidence of pharmacoeconomic benefit represents an important potential opportunity for nonclinical differentiation."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
2. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
3. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
4. Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
5. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
6. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
7. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
8. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
9. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
10. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
11. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):